Description
A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy
The study will be conducted in two parts:
Dose determination of Irinotecan Liposome Injection
A randomized, efficacy study of Irinotecan Liposome Injection versus Topotecan
SIMR (Sacramento/Valley Area): Please contact simr@sutterhealth.org about study RESILIENT-Ipsen
View study details on ClinicalTrials.govPrincipal Investigator
Co-Investigator(s)
Brian K. Kim, M.D, Sivakumar Reddy, M.D., Kristin N. Arreola, M.D., Vijay Suhag, M.D., Jasdeepa Nagi, M.D., Rajeswari Chellappah, M.D., Nitin Rohatgi, MD
Recruitment Status
Active, Not Recruiting
Funder
Ipsen Bioscience
Start Date
October 26, 2020
Related Studies
SEER Lung Cancer
Investigator: Tze-Ming Chen, M.D., FCCP
The Impact of Smoking, Comorbidities, and Race/Ethnicity on COVID-19 Infection and Disease Severity
Investigator: Jiang Li, Ph.D., MPH